

FIGURE 1




FIGURE 2A-F




FIGURE 2G




FIGURE 3A-B




FIGURE 3C-E






FIGURE 3F-H

G



F



H

FIGURE 3I




FIGURE 4



FIGURE 5




FIGURE 6





FIGURE 7

A



B




FIGURE 8




FIGURE 9A-D




FIGURE 10A-B





FIGURE 10C- D

C



D




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15





FIGURE 16A-B

A



B




FIGURE 17




FIGURE 18

HUMAN FORESKIN FIBROBLASTS CONTRACTION
EFFECTS OF HA-BINDING PEPTIDE
(1 ng/mL and 500 ng/mL)




FIGURE 19

HUMAN FORESKIN FIBROBLASTS CONTRACTION

**EFFECTS OF HA-BINDING PEPTIDE
(1 ng/mL to 500 µg/mL)**




FIGURE 20

HUMAN FORESKIN FIBROBLASTS CONTRACTION
EFFECTS OF RHAMM-MOTIF PEPTIDE
(1 ng/mL to 500 ug/mL)




FIGURE 21

**HUMAN FORESKIN FIBROBLASTS CONTRACTION
EFFECTS OF ANTI-EXON 5 ANTIBODY**




FIGURE 22

HUMAN FORESKIN FIBROBLASTS CONTRACTION

EFFECTS OF ANTI-EXON 9 ANTIBODY




FIGURE 23

**HUMAN FORESKIN FIBROBLASTS CONTRACTION
EFFECTS OF ANTI-CD44 ANTIBODY**

